Press release
Lupus Nephritis Pipeline Insights 2024: Therapies, Clinical Trials by DelveInsight | Roche, Equillium, BeiGene, Janssen R&D, Horizon Therapeutics, Novartis, Roche, AstraZeneca
"Lupus Nephritis Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/lupus-nephritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Lupus Nephritis Market.
The Lupus Nephritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Lupus Nephritis Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Lupus Nephritis treatment therapies with a considerable amount of success over the years.
*
Lupus Nephritis companies working in the treatment market are Inflection Biosciences, Roche, Equillium, BeiGene, Janssen Research & Development, Horizon Therapeutics, Novartis, Roche, AstraZeneca, Novartis, Alexion Pharmaceuticals, AstraZeneca, Equillium, and others, are developing therapies for the Lupus Nephritis treatment
*
Emerging Lupus Nephritis therapies in the different phases of clinical trials are- IBL-101, RG 6107, Itolizumab, Zanubrutinib, Guselkumab, Daxdilimab, Secukinumab, Obinutuzumab, GAZYVA, Saphnelo (Anifrolumab), Iscalimab, Cosentyx, Ravulizumab, Anifrolumab, Itolizumab, and others are expected to have a significant impact on the Lupus Nephritis market in the coming years.
*
In February 2024, ImmPACT Bio has received an $8 million grant from the California Institute for Regenerative Medicine (CIRM) for its Phase Ib/II clinical trial of IMPT-514, aimed at treating refractory lupus nephritis (LN) and systemic lupus erythematosus (SLE). IMPT-514 is a CD19/CD20-targeting bispecific chimeric antigen receptor (CAR) T-cell therapy designed to deplete autoreactive immune cells. This open-label dose escalation trial will enroll participants with active, refractory SLE who have previously undergone at least two standard-of-care therapies.
*
In September 2023, Kyverna Therapeutics, a clinical-stage cell therapy company focused on developing treatments for serious autoimmune diseases, announced that KYV-101 was generally well tolerated with no cases of immune effector cell-associated neurotoxicity syndrome (ICANS) reported during the standard 28-day post-infusion observation period for the first U.S. patient enrolled in its Phase 1 clinical trial for relapsed or refractory lupus nephritis (LN). The KYV-101 infusion took place earlier in July at the University of Colorado Anschutz Medical Campus.
*
In July 2023, Kyverna Therapeutics ("Kyverna"), a cell therapy company with the goal of creating a new class of treatments for severe autoimmune diseases, announced today that the Paul-Ehrlich-Institut (PEI) in Germany has approved its first Clinical Trial Application (CTA) for KYV101, a cutting-edge therapy for the treatment of lupus nephritis (LN). In order to treat autoimmune disorders caused by B cells, such as LN, KYV-101 is a unique, totally human anti-CD19 CAR T-cell therapy. It provides a ground-breaking strategy for battling autoimmune diseases by utilising the body's immune system
Lupus Nephritis Overview
Lupus nephritis is a serious complication of systemic lupus erythematosus (SLE), an autoimmune disease where the body's immune system mistakenly attacks its own tissues. In lupus nephritis, the immune system targets the kidneys, leading to inflammation and potentially causing kidney damage.
Get a Free Sample PDF Report to know more about Lupus Nephritis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/lupus-nephritis-pipeline-insight [https://www.delveinsight.com/report-store/lupus-nephritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Lupus Nephritis Drugs Under Different Phases of Clinical Development Include:
*
Secukinumab: Novartis
*
Obinutuzumab: Roche
*
GAZYVA: Roche
*
Saphnelo (Anifrolumab): AstraZeneca
*
Iscalimab: Novartis
*
IBL-101: Inflection Biosciences
*
RG 6107: Roche
*
Itolizumab: Equillium
*
Zanubrutinib: BeiGene
*
Guselkumab: Janssen Research & Development
*
Daxdilimab: Horizon Therapeutics
*
Cosentyx: Novartis
*
Ravulizumab: Alexion Pharmaceuticals
*
Anifrolumab: AstraZeneca
Lupus Nephritis Route of Administration
Lupus Nephritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Oral
*
Parenteral
*
Intravenous
*
Subcutaneous
*
Topical
Lupus Nephritis Molecule Type
Lupus Nephritis Products have been categorized under various Molecule types, such as
*
Monoclonal Antibody
*
Peptides
*
Polymer
*
Small molecule
*
Gene therapy
Lupus Nephritis Pipeline Therapeutics Assessment
*
Lupus Nephritis Assessment by Product Type
*
Lupus Nephritis By Stage and Product Type
*
Lupus Nephritis Assessment by Route of Administration
*
Lupus Nephritis By Stage and Route of Administration
*
Lupus Nephritis Assessment by Molecule Type
*
Lupus Nephritis by Stage and Molecule Type
DelveInsight's Lupus Nephritis Report covers around 25+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Lupus Nephritis product details are provided in the report. Download the Lupus Nephritis pipeline report to learn more about the emerging Lupus Nephritis therapies [https://www.delveinsight.com/sample-request/lupus-nephritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Lupus Nephritis Therapeutics Market include:
Key companies developing therapies for Lupus Nephritis are - Novartis, Novartis Pharmaceuticals, Hoffmann-La Roche, Janssen Research & Development, BeiGene, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Aurinia Pharmaceuticals, Roche, AstraZeneca, Boehringer Ingelheim, Alexion Pharmaceuticals, Omeros Corporation, Corestem, Inc., Bristol-Myers Squibb, Boehringer Ingelheim, Apellis Pharmaceuticals, AstraZeneca, Kezar Life Sciences, Equillium, Eledon Pharmaceuticals, Resolve Therapeutics, and others.
Lupus Nephritis Pipeline Analysis:
The Lupus Nephritis pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Lupus Nephritis with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Lupus Nephritis Treatment.
*
Lupus Nephritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Lupus Nephritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Lupus Nephritis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Lupus Nephritis drugs and therapies [https://www.delveinsight.com/sample-request/lupus-nephritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Lupus Nephritis Pipeline Market Drivers
*
Increasing Prevalence of Lupus Nephritis, increase in research and developmental activities are some of the important factors that are fueling the Lupus Nephritis Market.
Lupus Nephritis Pipeline Market Barriers
*
However, high-cost associated with the disease, lack of awareness among the patients about the disease and other factors are creating obstacles in the Lupus Nephritis Market growth.
Scope of Lupus Nephritis Pipeline Drug Insight
*
Coverage: Global
*
Key Lupus Nephritis Companies: Inflection Biosciences, Roche, Equillium, BeiGene, Janssen Research & Development, Horizon Therapeutics, Novartis, Roche, AstraZeneca, Novartis, Alexion Pharmaceuticals, AstraZeneca, Equillium, and others
*
Key Lupus Nephritis Therapies: IBL-101, RG 6107, Itolizumab, Zanubrutinib, Guselkumab, Daxdilimab, Secukinumab, Obinutuzumab, GAZYVA, Saphnelo (Anifrolumab), Iscalimab, Cosentyx, Ravulizumab, Anifrolumab, Itolizumab, and others
*
Lupus Nephritis Therapeutic Assessment: Lupus Nephritis current marketed and Lupus Nephritis emerging therapies
*
Lupus Nephritis Market Dynamics: Lupus Nephritis market drivers and Lupus Nephritis market barriers
Request for Sample PDF Report for Lupus Nephritis Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/lupus-nephritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Lupus Nephritis Report Introduction
2. Lupus Nephritis Executive Summary
3. Lupus Nephritis Overview
4. Lupus Nephritis- Analytical Perspective In-depth Commercial Assessment
5. Lupus Nephritis Pipeline Therapeutics
6. Lupus Nephritis Late Stage Products (Phase II/III)
7. Lupus Nephritis Mid Stage Products (Phase II)
8. Lupus Nephritis Early Stage Products (Phase I)
9. Lupus Nephritis Preclinical Stage Products
10. Lupus Nephritis Therapeutics Assessment
11. Lupus Nephritis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Lupus Nephritis Key Companies
14. Lupus Nephritis Key Products
15. Lupus Nephritis Unmet Needs
16 . Lupus Nephritis Market Drivers and Barriers
17. Lupus Nephritis Future Perspectives and Conclusion
18. Lupus Nephritis Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=lupus-nephritis-pipeline-insights-2024-therapies-clinical-trials-by-delveinsight-roche-equillium-beigene-janssen-rd-horizon-therapeutics-novartis-roche-astrazeneca]
Phone: +14699457679
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lupus Nephritis Pipeline Insights 2024: Therapies, Clinical Trials by DelveInsight | Roche, Equillium, BeiGene, Janssen R&D, Horizon Therapeutics, Novartis, Roche, AstraZeneca here
News-ID: 3568471 • Views: …
More Releases from ABNewswire
Bedrock Restoration - Water Fire Mold Damage Service, Expands Water Damage Repai …
Water Fire Mold Damage Service, a trusted provider of property restoration, has announced expanded service offerings to meet the growing demand for professional water damage solutions in the region. Known for their reliable, customer-focused approach, the company continues to support both homeowners and businesses in recovering from unexpected property damage caused by water, fire, or mold.
Responding to a Growing Need for Water Damage Restoration
Property owners across Minnesota are increasingly seeking…
Winkler Kurtz LLP Expands Resources to Handle Increased Demand for Personal Inju …
For individuals searching for personal injury attorneys, the expansion of Winkler Kurtz LLP's team means greater accessibility and reduced wait times for consultations. The firm's deep roots in the Port Jefferson Station community allow them to understand local nuances, such as common accident hotspots and specific regional legal precedents.
Port Jefferson Station has seen a notable rise in personal injury cases, driven by factors such as increased traffic congestion, construction activity,…
Protecting Property Value: Hose Bros Inc Highlights How Professional Power Washi …
For residents searching for power washing near me, Hose Bros Inc offers accessible and reliable services tailored to the Millsboro community. Their local expertise ensures an understanding of regional challenges, such as the impact of salt air on coastal properties or the tendency for humidity to promote mold growth in shaded areas. This knowledge allows them to customize their approach, selecting appropriate pressure levels and cleaning agents for different surfaces.
In…
![Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Prices](https://cdn.open-pr.com/9/1/914818326_g.jpg)
Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Price …
A 2025 cost guide to kitchen, bathroom, and full home remodeling in Tampa Bay, featuring expert insights from Craftline Remodeling on pricing, budgeting, and contractor selection.
Market Overview: Understanding Tampa Bay Remodeling Investment Trends
Tampa Bay's home remodeling market has experienced significant cost evolution in 2025, with project expenses varying dramatically across South Tampa, Carrollwood, Seminole Heights, Clearwater, St. Petersburg, and Wesley Chapel based on material choices, project scope, and contractor expertise.…
More Releases for Lupus
Cutaneous Lupus Erythematosus (CLE) Market
Introduction
Cutaneous Lupus Erythematosus (CLE) is a chronic autoimmune skin disorder, often associated with systemic lupus erythematosus (SLE), that presents as inflammation, rashes, and photosensitivity. While CLE is rarely fatal, it significantly affects patients' physical and emotional well-being, often leading to scarring, disfigurement, and social stigma.
Over the past decade, the market for CLE therapies has gained global importance as research into autoimmunity has accelerated and biologic therapies have transformed dermatology. Rising…
Prominent Cutaneous Lupus Erythematosus Market Trend for 2025: Advancements In C …
What combination of drivers is leading to accelerated growth in the cutaneous lupus erythematosus market?
The rising prevalence of skin infections is expected to drive the growth of the cutaneous lupus erythematosus (CLE) market. Skin infections are caused by microorganisms that invade the skin, triggering immune responses that can worsen symptoms in individuals with CLE. For example, the UK saw a 33.7% increase in MRSA cases caused by skin and soft…
Cutaneous Lupus Erythematosus (CLE) Market
Market Overview:
The Global Cutaneous Lupus Erythematosus (CLE) Market is forecasted to achieve a High CAGR during the period 2023-2030. CLE encompasses a spectrum of dermatological symptoms that may precede or accompany systemic lupus erythematosus (SLE), an autoimmune condition impacting multiple organs. Timely diagnosis and treatment of CLE can prevent the onset of severe systemic symptoms.
Market Dynamics:
Drivers:
Rise in Clinical Studies: Technological advancements leading to faster and accurate diagnosis have spurred additional…
Lupus Nephritis Treatment Market 2030
Global Lupus Nephritis Treatment market is expected to be worth roughly USD 8,048 million by 2030, growing at a CAGR of 7.3% during the forthcoming period of 2022-2030, according to Ameco Research
Lupus nephritis is one of the most rapidly spreading diseases over the globe. The increasing frequency of lupus nephritis and consumer awareness has fuelled the worldwide lupus nephritis treatment market. Another crucial factor driving the pace of growth of…
Lupus Erythematosus Market -API Insights, 2017
Summary
Orbis Research Present “Lupus Erythematosus-API Insights, 2017”
Description
The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market.
India and China produce a large percentage…
Global Systemic Lupus Erythematosus and Lupus Nephritis Market to Display 10.6% …
"The Report PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2025 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
MarketResearchReports.biz has announced the addition of a new report, titled “PharmaPoint: Systemic Lupus Erythematosus And Lupus Nephritis - Global Drug Forecast And Market Analysis To 2025,” to its expanding repository of research reports. The market…
